Panacea Biotec Soars to Record High on Dengue Vaccine Breakthrough!

Shares of $PANACEABIO surged as much as 17% intraday, extending gains for the sixth consecutive session and hitting a fresh all-time high of ₹647. The rally followed the company's announcement of the DENSTAR Project, a major initiative aimed at advancing the licensure of its dengue vaccine, DengiAll, across sub-Saharan Africa and supporting wider global adoption. The four-year program is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking, backed by the European Union. The development strengthens Panacea Biotec's global healthcare ambitions and has boosted investor optimism around its vaccine portfolio. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.